In Vitro and In Vivo Effects of Palmaria palmata Derived Peptides on Glucose Metabolism

[1]  J. Whooley,et al.  Identification and characterisation of peptides from a boarfish (Capros aper) protein hydrolysate displaying in vitro dipeptidyl peptidase-IV (DPP-IV) inhibitory and insulinotropic activity. , 2020, Food research international.

[2]  J. Holst,et al.  GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals. , 2020, The Journal of clinical endocrinology and metabolism.

[3]  W. Atlee,et al.  Update on type 2 diabetes mellitus drug treatment and drug usage-2020 , 2020 .

[4]  Alyce M. Martin,et al.  Mechanisms controlling hormone secretion in human gut and its relevance to metabolism , 2019, The Journal of endocrinology.

[5]  C. Deacon.  Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes , 2019, Front. Endocrinol..

[6]  A. Nongonierma,et al.  Features of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides from dietary proteins. , 2019, Journal of food biochemistry.

[7]  R. Gimeno,et al.  Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial , 2018, The Lancet.

[8]  G. Cagney,et al.  Casein Hydrolysate with Glycemic Control Properties: Evidence from Cells, Animal Models, and Humans. , 2018, Journal of Agricultural and Food Chemistry.

[9]  P. Flatt,et al.  Apelin-13 analogues show potent in vitro and in vivo insulinotropic and glucose lowering actions , 2018, Peptides.

[10]  M. Tschöp,et al.  Gut hormone polyagonists for the treatment of type 2 diabetes , 2018, Peptides.

[11]  P. Dhulster,et al.  Using Caco-2 cells as novel identification tool for food-derived DPP-IV inhibitors. , 2017, Food Research International.

[12]  N. Irwin,et al.  An enzymatically stable GIP/xenin hybrid peptide restores GIP sensitivity, enhances beta cell function and improves glucose homeostasis in high-fat-fed mice , 2016, Diabetologia.

[13]  N. Irwin,et al.  Biological Activity and Antidiabetic Potential of C-Terminal Octapeptide Fragments of the Gut-Derived Hormone Xenin , 2016, PloS one.

[14]  N. Irwin,et al.  New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders. , 2015, World journal of diabetes.

[15]  P. Flatt,et al.  Functional GIP receptors play a major role in islet compensatory response to high fat feeding in mice. , 2015, Biochimica et biophysica acta.

[16]  N. Irwin,et al.  A Novel CCK-8/GLP-1 Hybrid Peptide Exhibiting Prominent Insulinotropic, Glucose-Lowering, and Satiety Actions With Significant Therapeutic Potential in High-Fat–Fed Mice , 2015, Diabetes.

[17]  P. Harnedy,et al.  Purification and identification of dipeptidyl peptidase (DPP) IV inhibitory peptides from the macroalga Palmaria palmata. , 2015, Food chemistry.

[18]  A. Cardador-Martínez,et al.  Proteins and bioactive peptides , 2014 .

[19]  T. Vilsbøll,et al.  Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. , 2014, European journal of internal medicine.

[20]  P. Jakeman,et al.  Food protein hydrolysates as a source of dipeptidyl peptidase IV inhibitory peptides for the management of type 2 diabetes , 2013, Proceedings of the Nutrition Society.

[21]  J. Conlon,et al.  Frog skin peptides (tigerinin-1R, magainin-AM1, -AM2, CPF-AM1, and PGla-AM1) stimulate secretion of glucagon-like peptide 1 (GLP-1) by GLUTag cells. , 2013, Biochemical and biophysical research communications.

[22]  J. Holst,et al.  Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes , 2011, Diabetes Care.

[23]  Lorraine Brennan,et al.  Amino Acid Metabolism, β-Cell Function, and Diabetes , 2006, Diabetes.

[24]  M. Krebs,et al.  Effects of dietary protein on glucose homeostasis , 2006, Current opinion in clinical nutrition and metabolic care.

[25]  P. Flatt,et al.  Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents. , 2004, Current pharmaceutical design.

[26]  C. Bailey,et al.  Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice , 1981, Diabetologia.

[27]  R. Pederson,et al.  Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. , 2003, Endocrinology.

[28]  R. Pederson,et al.  Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. , 2003, Endocrinology.

[29]  Y. Seino,et al.  Gastric inhibitory polypeptide activates MAP kinase through the wortmannin-sensitive and -insensitive pathways. , 1997, Biochemical and biophysical research communications.

[30]  E. Ah-Sing,et al.  Characterization of a Novel Glucose-Responsive Insulin-Secreting Cell Line, BRIN-BD11, Produced by Electrofusion , 1996, Diabetes.